当前位置: 首页 >> 检索结果
共有 18941 条符合本次的查询结果, 用时 7.8166181 秒

1041. Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed.

作者: Christopher D Byrne.;Giovanni Targher.
来源: Gut. 2022年71卷9期1695-1696页

1042. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.

作者: Steffie Revia.;Agnieszka Seretny.;Lena Wendler.;Ana Banito.;Christoph Eckert.;Kersten Breuer.;Anand Mayakonda.;Pavlo Lutsik.;Matthias Evert.;Silvia Ribback.;Suchira Gallage.;Ismaiel Chikh Bakri.;Kai Breuhahn.;Peter Schirmacher.;Stefan Heinrich.;Matthias M Gaida.;Mathias Heikenwälder.;Diego F Calvisi.;Christoph Plass.;Scott W Lowe.;Darjus F Tschaharganeh.
来源: Gut. 2022年71卷8期1613-1628页
Large-scale genome sequencing efforts of human tumours identified epigenetic modifiers as one of the most frequently mutated gene class in human cancer. However, how these mutations drive tumour development and tumour progression are largely unknown. Here, we investigated the function of the histone demethylase KDM6A in gastrointestinal cancers, such as liver cancer and pancreatic cancer.

1043. What to do about the leaky gut.

作者: Michael Camilleri.;Adrian Vella.
来源: Gut. 2022年71卷2期424-435页

1044. Deciphering the vedolizumab dosing conundrum in IBD: when less is more.

作者: Timon Erik Adolph.;Britta Siegmund.
来源: Gut. 2022年71卷8期1455-1456页

1045. Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?

作者: Annieke C G van Baar.;Suzanne Meiring.;Frits Holleman.;David Hopkins.;Geltrude Mingrone.;Jacques Devière.;Max Nieuwdorp.;Jacques J G H M Bergman.
来源: Gut. 2021年70卷11期2196-2204页

1046. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults.

作者: Jonathon Snook.;Neeraj Bhala.;Ian L P Beales.;David Cannings.;Chris Kightley.;Robert Ph Logan.;D Mark Pritchard.;Reena Sidhu.;Sue Surgenor.;Wayne Thomas.;Ajay M Verma.;Andrew F Goddard.
来源: Gut. 2021年70卷11期2030-2051页
Iron deficiency anaemia (IDA) is a major cause of morbidity and burden of disease worldwide. It can generally be diagnosed by blood testing and remedied by iron replacement therapy (IRT) using the oral or intravenous route. The many causes of iron deficiency include poor dietary intake and malabsorption of dietary iron, as well as a number of significant gastrointestinal (GI) pathologies. Because blood is iron-rich it can result from chronic blood loss, and this is a common mechanism underlying the development of IDA-for example, as a consequence of menstrual or GI blood loss.Approximately a third of men and postmenopausal women presenting with IDA have an underlying pathological abnormality, most commonly in the GI tract. Therefore optimal management of IDA requires IRT in combination with appropriate investigation to establish the underlying cause. Unexplained IDA in all at-risk individuals is an accepted indication for fast-track secondary care referral in the UK because GI malignancies can present in this way, often in the absence of specific symptoms. Bidirectional GI endoscopy is the standard diagnostic approach to examination of the upper and lower GI tract, though radiological scanning is an alternative in some situations for assessing the large bowel. In recurrent or refractory IDA, wireless capsule endoscopy plays an important role in assessment of the small bowel.IDA may present in primary care or across a range of specialties in secondary care, and because of this and the insidious nature of the condition it has not always been optimally managed despite the considerable burden of disease- with investigation sometimes being inappropriate, incorrectly timed or incomplete, and the role of IRT for symptom relief neglected. It is therefore important that contemporary guidelines for the management of IDA are available to all clinicians. This document is a revision of previous British Society of Gastroenterology guidelines, updated in the light of subsequent evidence and developments.

1047. Chief cell plasticity is the origin of metaplasia following acute injury in the stomach mucosa.

作者: Brianna Caldwell.;Anne R Meyer.;Jared A Weis.;Amy C Engevik.;Eunyoung Choi.
来源: Gut. 2022年71卷6期1068-1077页
Metaplasia arises from differentiated cell types in response to injury and is considered a precursor in many cancers. Heterogeneous cell lineages are present in the reparative metaplastic mucosa with response to injury, including foveolar cells, proliferating cells and spasmolytic polypeptide-expressing metaplasia (SPEM) cells, a key metaplastic cell population. Zymogen-secreting chief cells are long-lived cells in the stomach mucosa and have been considered the origin of SPEM cells; however, a conflicting paradigm has proposed isthmal progenitor cells as an origin for SPEM.

1048. Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC).

作者: Manuela Salvucci.;Nyree Crawford.;Katie Stott.;Susan Bullman.;Daniel B Longley.;Jochen H M Prehn.
来源: Gut. 2022年71卷8期1600-1612页
Transcriptomic-based subtyping, consensus molecular subtyping (CMS) and colorectal cancer intrinsic subtyping (CRIS) identify a patient subpopulation with mesenchymal traits (CMS4/CRIS-B) and poorer outcome. Here, we investigated the relationship between prevalence of Fusobacterium nucleatum (Fn) and Fusobacteriales, CMS/CRIS subtyping, cell type composition, immune infiltrates and host contexture to refine patient stratification and to identify druggable context-specific vulnerabilities.

1049. Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.

来源: Gut. 2021年70卷10期e7页

1050. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.

作者: Samuel Anthony Lachlan Hall.;Sara Vogrin.;Olivia Wawryk.;Gareth S Burns.;Kumar Visvanathan.;Vijaya Sundararajan.;Alexander Thompson.
来源: Gut. 2022年71卷8期1629-1641页
Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB.

1051. Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.

作者: Jihyun An.;Ha Il Kim.;Bora Oh.;Yoo-Jin Oh.;Ji-Hye Oh.;Wonkyung Kim.;Chang Ohk Sung.;Ju Hyun Shim.
来源: Gut. 2022年71卷6期1234-1236页

1052. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.

作者: Feng Wang.;You-Sheng Huang.;Hao-Xiang Wu.;Zi-Xian Wang.;Ying Jin.;Yi-Chen Yao.;Yan-Xing Chen.;Qi Zhao.;Shifu Chen.;Ming-Ming He.;Hui-Yan Luo.;Miao-Zhen Qiu.;De-Shen Wang.;Feng-Hua Wang.;Mingyan Xu.;Yu-Hong Li.;Rui-Hua Xu.
来源: Gut. 2022年71卷7期1340-1349页
Circulating tumour DNA (ctDNA) sequencing is increasingly used in the clinical management of patients with colorectal cancer. However, the genomic heterogeneity in ctDNA during treatments and its impact on clinical outcomes remain largely unknown.

1053. STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis.

作者: Ruby E Dawson.;Virginie Deswaerte.;Alison C West.;Ke Tang.;Alice J West.;Jesse J Balic.;Linden J Gearing.;Mohamed I Saad.;Liang Yu.;Yonghui Wu.;Prithi S Bhathal.;Beena Kumar.;Jayati T Chakrabarti.;Yana Zavros.;Hiroko Oshima.;Dennis M Klinman.;Masanobu Oshima.;Patrick Tan.;Brendan J Jenkins.
来源: Gut. 2022年71卷8期1515-1531页
The absent in melanoma 2 (AIM2) cytosolic pattern recognition receptor and DNA sensor promotes the pathogenesis of autoimmune and chronic inflammatory diseases via caspase-1-containing inflammasome complexes. However, the role of AIM2 in cancer is ill-defined.

1054. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.

作者: Tracey G Simon.;Bjorn Roelstraete.;Hannes Hagström.;Johan Sundström.;Jonas F Ludvigsson.
来源: Gut. 2022年71卷9期1867-1875页
Some data suggest a positive association between non-alcoholic fatty liver disease (NAFLD) and incident major adverse cardiovascular events (MACEs). However, data are lacking from large cohorts with liver histology, which remains the gold standard for staging NAFLD severity.

1055. Diet quality and risk and severity of COVID-19: a prospective cohort study.

作者: Jordi Merino.;Amit D Joshi.;Long H Nguyen.;Emily R Leeming.;Mohsen Mazidi.;David A Drew.;Rachel Gibson.;Mark S Graham.;Chun-Han Lo.;Joan Capdevila.;Benjamin Murray.;Christina Hu.;Somesh Selvachandran.;Alexander Hammers.;Shilpa N Bhupathiraju.;Shreela V Sharma.;Carole Sudre.;Christina M Astley.;Jorge E Chavarro.;Sohee Kwon.;Wenjie Ma.;Cristina Menni.;Walter C Willett.;Sebastien Ourselin.;Claire J Steves.;Jonathan Wolf.;Paul W Franks.;Timothy D Spector.;Sarah Berry.;Andrew T Chan.
来源: Gut. 2021年70卷11期2096-2104页
Poor metabolic health and unhealthy lifestyle factors have been associated with risk and severity of COVID-19, but data for diet are lacking. We aimed to investigate the association of diet quality with risk and severity of COVID-19 and its interaction with socioeconomic deprivation.

1056. Stool microRNA profiling- dumpster diving for a master marker?

作者: Anna Heintz-Buschart.
来源: Gut. 2022年71卷7期1244-1245页

1057. Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.

作者: Emily Becker.;Mark Dedden.;Christine Gall.;Maximilian Wiendl.;Arif Bülent Ekici.;Anja Schulz-Kuhnt.;Anna Schweda.;Caroline Voskens.;Ahmed Hegazy.;Francesco Vitali.;Raja Atreya.;Tanja Martina Müller.;Imke Atreya.;Markus F Neurath.;Sebastian Zundler.
来源: Gut. 2022年71卷8期1551-1566页
The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of vedolizumab.

1058. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma.

作者: Feng Chen.;Xudong Dai.;Chang-Chun Zhou.;Ke-Xin Li.;Yu-Juan Zhang.;Xiao-Ying Lou.;Yuan-Min Zhu.;Yan-Lai Sun.;Bao-Xiang Peng.;Wei Cui.
来源: Gut. 2022年71卷7期1315-1325页
To profile gut microbiome-associated metabolites in serum and investigate whether these metabolites could distinguish individuals with colorectal cancer (CRC) or adenoma from normal healthy individuals.

1059. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.

作者: Raghav Sundar.;Kie-Kyon Huang.;Vikrant Kumar.;Kalpana Ramnarayanan.;Deniz Demircioglu.;Zhisheng Her.;Xuewen Ong.;Zul Fazreen Bin Adam Isa.;Manjie Xing.;Angie Lay-Keng Tan.;David Wai Meng Tai.;Su Pin Choo.;Weiwei Zhai.;Jia Qi Lim.;Meghna Das Thakur.;Luciana Molinero.;Edward Cha.;Marcella Fasso.;Monica Niger.;Filippo Pietrantonio.;Jeeyun Lee.;Anand D Jeyasekharan.;Aditi Qamra.;Radhika Patnala.;Arne Fabritius.;Mark De Simone.;Joe Yeong.;Cedric Chuan Young Ng.;Sun Young Rha.;Yukiya Narita.;Kei Muro.;Yu Amanda Guo.;Anders Jacobsen Skanderup.;Jimmy Bok Yan So.;Wei Peng Yong.;Qingfeng Chen.;Jonathan Göke.;Patrick Tan.
来源: Gut. 2022年71卷7期1277-1288页
Epigenomic alterations in cancer interact with the immune microenvironment to dictate tumour evolution and therapeutic response. We aimed to study the regulation of the tumour immune microenvironment through epigenetic alternate promoter use in gastric cancer and to expand our findings to other gastrointestinal tumours.

1060. Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer.

作者: Caitlin C Murphy.;Piera M Cirillo.;Nickilou Y Krigbaum.;Amit G Singal.;MinJae Lee.;Timothy Zaki.;Ezra Burstein.;Barbara A Cohn.
来源: Gut. 2022年71卷7期1332-1339页
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Obesity is a well-established risk factor for CRC, and fetal or developmental origins of obesity may underlie its effect on cancer in adulthood. We examined associations of maternal obesity, pregnancy weight gain, and birth weight and CRC in adult offspring.
共有 18941 条符合本次的查询结果, 用时 7.8166181 秒